Effectiveness of opioid rotation in the control of cancer pain: The ROTODOL Study
DOI:
https://doi.org/10.5055/jom.2014.0236Keywords:
analgesics, opioid/administration and dosage, pain, neoplasmsAbstract
Objective: To assess the effectiveness of opioid rotation (OR) to manage cancer pain. To describe the adverse events (AEs) associated with OR.
Setting: Thirty-nine tertiary hospital services.
Patients: Sixty-seven oncological patients with cancer-related pain treated at outpatient clinics.
Intervention: Prospective multicenter study. Pain intensity was scored using a Numerical Rating Scale (NRS) of 0-10. Average pain (AP) intensity in the last 24 hours, breakthrough pain (BTP), and the number of episodes of BTP on the days before and 1 week after OR were assessed. The pre-OR and post-OR opioid were recorded. The presence and intensity of any AEs occurring after OR were also recorded.
Results: In the 67 patients evaluated, 75 ORs were recorded. In all cases, the main reason for OR was poor pain control. Pain intensity decreased by ≥2 points after OR in 75.4 percent and 57.8 percent of cases for AP and BTP, respectively. If the initial NRS score was ≥4, a decrease below <4 accounted for 50.9 percent and 32.3 percent of cases for AP and BTP, respectively. The number of episodes of BTP also decreased significantly (p < 0.001). A total of 107 AEs were reported, most of which were mild in intensity, with gastrointestinal symptoms predominating.
Conclusions: Opioid rotation appears to be both safe and effective in the management of basal and breakthrough cancer pain.
References
World Health Organization: WHO Cancer Pain Relief, with a Guide to Opioid Availability. Geneva: World Health Organization, 1996.
Zech DF, Grond S, Lynch J, et al.: Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain. 1995; 63(1): 65-76. DOI: https://doi.org/10.1016/0304-3959(95)00017-M
Porta-Sales J, Gómez-Batiste X, Tuca-Rodriguez A, et al.: WHO analgesic ladder—Or lift? Eur J Palliat Care. 2003; 10: 105-109.
Hanks GW, Conno F, Cherny N, et al.: Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer. 2001; 84(5): 587-593. DOI: https://doi.org/10.1054/bjoc.2001.1680
Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 1: Clinical considerations. J Pain Symptom Manage. 2001; 21(2): 144-150. DOI: https://doi.org/10.1016/S0885-3924(00)00228-1
González-Barboteo J, Trelis-Navarro J, Tuca-Rodríguez A, et al.: Opioid rotation: A therapeutic choice in the management of refractory cancer pain. Med Clin (Barc). 2010; 135(13): 617-622. DOI: https://doi.org/10.1016/j.medcli.2010.06.006
Quigley C: Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004; 3(3): CD004847. DOI: https://doi.org/10.1002/14651858.CD004847
Mercadante S, Bruera E: Opioid switching: A systematic and critical review. Cancer Treat Rev. 2006; 32(4): 304-315. DOI: https://doi.org/10.1016/j.ctrv.2006.03.001
Vadalouca A, Moka E, Argyra E, et al.: Opioid rotation in patients with cancer: A review of the current literature. J Opioid Manag. 2008; 4(4): 213-250. DOI: https://doi.org/10.5055/jom.2008.0027
Mercadante S: Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer. 1999; 86(9): 1856-1866. DOI: https://doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G
Ross JR, Riley J, Quigley C, et al.: Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006; 11(7): 765-773. DOI: https://doi.org/10.1634/theoncologist.11-7-765
Pasternak GW: Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001; 22(2): 67-70. DOI: https://doi.org/10.1016/S0165-6147(00)01616-3
Bolan EA, Tallarida RJ, Pasternak GW: Synergy between mu opioid ligands: Evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther. 2002; 303(2): 557-562. DOI: https://doi.org/10.1124/jpet.102.035881
Dong Z, Cao J, Xu L: Opiate withdrawal modifies synaptic plasticity in subicular-nucleus accumbens pathway in vivo. Neuroscience. 2007; 144(3): 845-854. DOI: https://doi.org/10.1016/j.neuroscience.2006.10.018
Pu L, Bao G-B, Xu N-J, et al.: Hippocampal long-term potentiation is reduced by chronic opiate treatment and can be restored by re-exposure to opiates. J Neurosci. 2002; 22(5): 1914-1921. DOI: https://doi.org/10.1523/JNEUROSCI.22-05-01914.2002
Ho S-T, Wang J-J, Huang J-C, et al.: The magnitude of acute tolerance to morphine analgesia: Concentration-dependent or time-dependent? Anesth Analg. 2002; 95(4): 948-951. DOI: https://doi.org/10.1213/00000539-200210000-00029
Fischer BD, Carrigan KA, Dykstra LA: Effects of N-methyld-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice. J Pain. 2005; 6(7): 425-433. DOI: https://doi.org/10.1016/j.jpain.2005.02.003
Baker AK, Hoffmann VLH, Meert TF: Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain. Pharmacol Biochem Behav. 2002; 74(1): 73-86. DOI: https://doi.org/10.1016/S0091-3057(02)00961-9
Duttaroy A, Yoburn BC: The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995; 82(5): 1226-1236. DOI: https://doi.org/10.1097/00000542-199505000-00018
Riley J, Ross JR, Rutter D, et al.: No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006; 14(1): 56-64. DOI: https://doi.org/10.1007/s00520-005-0843-2
Vigano A, Fan D, Bruera E: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 1996; 67(1): 115-119. DOI: https://doi.org/10.1016/0304-3959(96)03112-0
Cherny NJ, Chang V, Frager G, et al.: Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995; 76(7): 1283-1293. DOI: https://doi.org/10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0
De Stoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995; 10(5): 378-384. DOI: https://doi.org/10.1016/0885-3924(95)90924-C
Ashby MA, Martin P, Jackson KA: Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust. 1999; 170(2): 68-71. DOI: https://doi.org/10.5694/j.1326-5377.1999.tb126885.x
Bruera E, Pereira J, Watanabe S, et al.: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996; 78(4): 852-857. DOI: https://doi.org/10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T
Gagnon B, Bruera E: Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage. 1999; 18(2): 120-125. DOI: https://doi.org/10.1016/S0885-3924(99)00049-4
Mercadante S, Ferrera P, Villari P, et al.: Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage. 2009; 37(4): 632-641. DOI: https://doi.org/10.1016/j.jpainsymman.2007.12.024
Bruera E, MacMillan K, Hanson J, et al.: The Edmonton Staging System for cancer pain: Preliminary report. Pain. 1989; 37(2): 203-209. DOI: https://doi.org/10.1016/0304-3959(89)90131-0
Porta-Sales J, Rodriguez-Mesa D, Sala-Rovira C: Dolor. In Porta-Sales J, Gómez-Batiste X, Tuca-Rodríguez A (eds.): Manual de control de síntomas en pacientes con cáncer avanzado y terminal. 2nd ed. Madrid: Arán Ediciones S.L., 2008: 45-111.
U.S. Department of Health and Human Services. National Institutes of Health National: Common Terminology Criteria for Adverse Events (CTCAE) version v4.03. 2010. Available at http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf. Accessed November 11, 2014.
Porta-Sales J, Codorniu N, Gómez-Batiste X, et al.: Patient appointment process, symptom control and prediction of follow-up compliance in a palliative care outpatient clinic. J Pain Symptom Manage. 2005; 30(2): 145-153. DOI: https://doi.org/10.1016/j.jpainsymman.2005.03.008
Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer. 1982; 50(9): 1913-1918. DOI: https://doi.org/10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R
Serlin RC, Mendoza TR, Nakamura Y, et al.: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61(2): 277-284. DOI: https://doi.org/10.1016/0304-3959(94)00178-H
Müller-Busch HC, Lindena G, Tietze K, et al.: Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain. 2005; 9(5): 571-579. DOI: https://doi.org/10.1016/j.ejpain.2004.12.003
Mercadante S, Casuccio A, Tirelli W, et al.: Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009; 17(6): 715-718. DOI: https://doi.org/10.1007/s00520-008-0546-6
Gatti A, Reale C, Luzi M, et al.: Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clin Drug Investig. 2010; 30(Suppl 2): 39-47. DOI: https://doi.org/10.2165/1158413-S0-000000000-00000
Farrar JT: What is clinically meaningful: Outcome measures in pain clinical trials. Clin J Pain. 2000; 16(2 Suppl): S106-S112. DOI: https://doi.org/10.1097/00002508-200006001-00018
Farrar JT, Portenoy RK, Berlin JA, et al.: Defining the clinically important difference in pain outcome measures. Pain. 2000; 88(3): 287-294. DOI: https://doi.org/10.1016/S0304-3959(00)00339-0
Kloke M, Rapp M, Bosse B, et al.: Toxicity and/or insufficient analgesia by opioid therapy: Risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer. 2000; 8(6): 479-486. DOI: https://doi.org/10.1007/s005200000153
Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 2: Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage. 2001; 21(3): 255-264. DOI: https://doi.org/10.1016/S0885-3924(00)00236-0
Collin E, Poulain P, Gauvain-Piquard A, et al.: Is disease progression the major factor in morphine “tolerance” in cancer pain treatment? Pain. 1993; 55(3): 319-326. DOI: https://doi.org/10.1016/0304-3959(93)90007-C
Fainsinger RL, Nekolaichuk CL, Lawlor PG, et al.: A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage. 2005; 29(3): 224-237. DOI: https://doi.org/10.1016/j.jpainsymman.2004.05.008
Mercadante S, Ferrera P, Villari P, et al.: Hyperalgesia: An emerging iatrogenic syndrome. J Pain Symptom Manage. 2003; 26(2): 769-775. DOI: https://doi.org/10.1016/S0885-3924(03)00258-6
Mercadante S, Arcuri E: Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005; 22(4): 291-294. DOI: https://doi.org/10.1177/104990910502200411
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved